Cardiovascular disease (CVD) remains a major global health issue, with atherosclerosis as a primary cause. Early interventions are crucial since traditional risk factor-based scores do not effectively identify individuals at risk for developing atherosclerotic vascular disease. Current pharmacological treatments target established risk factors; however, residual cardiovascular risk persists in treated patients. Recent studies indicate that gut microbiota metabolism may be linked to the progression of atherosclerosis. Efforts to identify microbial metabolites associated with early stages of the disease could enhance understanding of atherosclerosis and lead to improved prevention and therapies.
Atherosclerosis is a complex multifactorial disease whose prevention is based on traditional cardiovascular risk factor-based scores that do not identify individuals at risk for atherosclerotic vascular disease at early stages.
Crosstalk between the metabolisms of the microbiota and host contributes to cardiovascular disease. Few gut microbiota-dependent metabolites that correlate with late stages of the disease have been described.
Collection
[
|
...
]